Therapeutic Approach

Archive: May, 2018

Ritter Pharmaceuticals Announces Appointment of John W. Beck as Chief Financial Officer

LOS ANGELES (May 29, 2018) – Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases (GI) with an initial focus on the development of RP-G28, a drug candidate with the potential to be the first FDA-approved treatment for lactose […]

Leave Your Comments »

Ritter Pharmaceuticals to Present Two Posters at Digestive Disease Week 2018 Highlighting Treatment Data of RP-G28 for Lactose Intolerance

LOS ANGELES (May 22, 2018) – Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with an initial focus on the development of the first FDA-approved treatment for lactose intolerance, today announces it will be presenting two posters of […]

Leave Your Comments »

Ritter Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Updates

LOS ANGELES (May 15, 2018) – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with an initial focus on the development of the first FDA-approved treatment for lactose intolerance, today reported financial results for the first quarter ended […]

Leave Your Comments »

Ritter Pharmaceuticals Selects Medpace as its Clinical Research Organization for Pivotal Phase 3 Clinical Trial of RP-G28 in Lactose Intolerance

LOS ANGELES (May 3, 2018) – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with an initial focus on the development of the first FDA-approved treatment for lactose intolerance, today announces that it has signed an agreement with […]

Leave Your Comments »

Featuring Recent Posts WordPress Widget development by YD